Whitehawk Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
2 HEADQUARTERS PLAZA, MORRISTOWN, NJ, 07960
Mailing Address
2 HEADQUARTERS PLAZA, MORRISTOWN, NJ, 07960
Phone
551-321-2234
Fiscal Year End
1231
EIN
611547850
Financial Overview
FY2025
$150.83M
Total Assets
$37.57M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 3 Initial insider ownership report | December 2, 2025 | View on SEC |
| 4 Insider stock transaction report | December 2, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 6, 2025 | View on SEC |
| 8-K Current report of material events | November 6, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | August 25, 2025 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Clinical-stage biopharmaceutical company focused on novel therapeutic candidates for unmet medical needs.
- Leverages proprietary scientific platforms for drug discovery and development.
Insider Trading
SELL
3 insiders
3 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.